LSKL, Inhibitor of Thrombospondin (TSP-1) TFA, a tetrapeptide derived from latency-associated protein (LAP)-TGFβ, acts as a competitive antagonist of TGF-β1.
BeKm-1 TFA is a potent, selective blocker of the KV11.1 (hERG) channel, demonstrating specificity for KV11.1 over 14 other potassium channels. This compound dose-dependently prolongs the QTc interval in isolated rabbit hearts, affirming its role as a selective inhibitor.
C-Type Natriuretic Peptide (CNP) (1-22), human (TFA), is a 22 amino acid fragment of CNP and functions as an agonist for the natriuretic peptide receptor B (NPR-B). It can inhibit cAMP synthesis, which is induced by histamine, 5-HT, or Forskolin. Additionally, CNP exhibits strong endothelial-derived relaxation properties and acts as a growth inhibitor.
Angiotensin I II (1-6) TFA is a chemical compound comprising amino acids 1-6. It is derived from the Angiotensin I II peptide, which is formed by the cleavage of the precursor angiotensinogen by renin. The resulting Angiotensin I is then hydrolyzed by angiotensin-converting enzyme (ACE) to produce biologically active Angiotensin II. Angiotensin II has been extensively studied for its potential applications in the treatment of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy[1][2][3].